Arvinas Inc to Discuss the Phase 1 Dose Escalation Data and Interim Data from the Phase 2 ARDENT Trial Transcript
Thank you for standing by, and welcome to the Arvinas ASCO GU data conference call. (Operator Instructions) As a reminder, today's conference call is being recorded.
I would now like to turn the conference over to your host, Mr. Jeff Boyle, Vice President of Investor Relations. Please go ahead.
Good morning, everyone, and thank you for joining us to discuss the ARV-110, which we now refer to as bavdegalutamide, Phase 1 dose escalation and interim ARDENT Phase 2 dose expansion trial results that will be presented later today at the ASCO GU conference.
Earlier this morning, we issued a press release highlighting the data, which can be accessed in the Investors section of our website at arvinas.com. With me this morning are: Arvinas President and Chief Executive Officer, John Houston; and Arvinas Chief Medical Officer, Ron Peck; Ian Taylor, our Chief Scientific Officer, will join for the Q&A portion of the call.
Before we begin, I would like to remind you that today's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |